Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab

Puxkandl, Viktoria; Hoetzenecker, Wolfram; Altrichter, Sabine

doi:10.5414/alx02382e

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic spontaneous urticaria (CSU) entails the absence of identified causes of urticaria and can be highly debilitating and recalcitrant to standard treatments. A total of 14 patients were reported that had failed standard therapies with antihistamines, omalizumab and/or ciclosporin and were subsequently treated with dupilumab (12/14) or a combination of dupilumab and omalizumab (2/14) ( Table 5 ) [ 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 ]. Complete sustained resolutions were reported in 10/14 patients by clinical evaluation and the 7-day urticaria activity score (UAS7) or urticaria control test (UCT); a UAS7 of 0 was reported in 5 of these cases.…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

Dupilumab: Evaluating its role in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders – Part I

Bubna,

Viplav

2024

JSSTD

View full text Add to dashboard Cite

Dupilumab is a fully human monoclonal IgG4 antibody that targets IL-4 and IL-13 signaling pathways. It is approved by the US-FDA for the treatment of atopic dermatitis and prurigo nodularis. Besides, it has shown efficacy in various off-label dermatologic conditions. Part I of this review will elaborate on the utility of dupilumab in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders.

show abstract

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

Asero,

Calzari,

Vaienti

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients’ quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold. If symptoms persist despite this adjustment, the next step involves the use of omalizumab, a monoclonal anti-IgE antibody, which has shown efficacy in the majority of cases. However, a subset of patients remains refractory, necessitating alternative treatments such as immunosuppressive agents like cyclosporine or azathioprine. To address these unmet needs, several new therapeutic targets are being explored. Among them, significant attention is being given to drugs that block Bruton’s tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation. Therapies like dupilumab, which target the interleukin-4 (IL-4) and IL-13 pathways, are also under investigation. Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies. These emerging treatments offer new options for patients with difficult-to-treat CSU and have the potential to modify the natural course of the disease by targeting key immune pathways, helping to achieve longer-term remission. Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.

show abstract

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab

Cited by 3 publications

References 10 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab: Evaluating its role in atopic dermatitis, prurigo nodularis, eczemas, urticaria, alopecia areata and vesiculobullous disorders – Part I

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

Contact Info

Product

Resources

About